Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis

Autor: Daniela Graham, Philip S Helliwell, Christopher Ritchlin, Alexis Ogdie, Jon T Giles, Rebecca Germino, Lori Stockert, Pamela Young, Wael Joseph, Rajiv Mundayat, Juan J Gómez-Reino
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: RMD Open, Vol 7, Iss 1 (2021)
Druh dokumentu: article
ISSN: 2056-5933
DOI: 10.1136/rmdopen-2020-001486
Popis: Objectives This post-hoc analysis explored the impact of body mass index (BMI) on tofacitinib efficacy/safety in patients with active psoriatic arthritis (PsA).Methods Data were pooled from two phase 3 studies (NCT01877668; NCT01882439). Analyses included patients randomised to tofacitinib 5/10 mg two times a day or placebo, stratified by baseline BMI:
Databáze: Directory of Open Access Journals